Fractyl Health: initial REVEAL-1 data show weight maintenance post-GLP-1 discontinuation; REMAIN-1 enrollment strong

FRACTYL HEALTH, INC.

First REVEAL-1 patient achieved 15% total body weight loss on tirzepatide, then maintained weight 1 month after Revita post-discontinuation.
Prior studies show average 3% weight regain within 4 weeks of GLP-1 discontinuation, highlighting Revita potential.
Over 100 patients enrolled across 8 sites in REMAIN-1 study in less than 4 months; high demand.
REVEAL-1 cohort data presentation delayed to Q1 2025 due to holiday scheduling; mid-point analysis expected Q2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.